Inspiritol

Inspiritol is an experimental drug that aims to treat post-viral illness and respiratory distress. Inspiritol is both the name of the company company the drug and the name of the drug. Inspiritol has been reported to have been used experimentally on a small number of ME/CFS patients, long COVID patients, and people with flu, COPD or asthma.

Theory
Inspiritol aims to alter the oral microbiome to reduce levels of bacteria that have previously been linked to inflammation. In a recent small study whole genome sequencing was used to sample the oral microbiome of patients who tested positive for COVID-19 at an emergency room, fourteen of the patients later developed long COVID. The study's long COVID patients were found to have changes 19 species of bacteria in their oral microbiome that were not found in patients without long COVID.

Inspiritol consists of a number of different substances, some of which are believed to have anti-inflammatory, antiviral, or antibacterial effects.

Evidence
No clinical trials or case studies of Inspiritol have been published yet.

Clinicians
Inspiritol has been used in clinical trials by the following ME/CFS researchers:
 * John Salerno, who helped develop Inspiritol
 * Anna Gill, University of Massachusetts Chan Medical School
 * Liisa Selin, University of Massachusetts Chan Medical School

Risks and safety
Inspiritol remains in clinical trials so the side effects and risks are largely unknown, and it has not yet been given FDA approval.

Costs and availability
Inspiritol is an inhaled drug which is highly restricted due to not yet being FDA-approved.

Learn more

 * Inspiritol website